LEO Pharma
Highly Engaged Employees
Manufacturing · Denmark · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Industriparken 55, Ballerup, Region Hove...Phone Number
+45 44945888Website
www.leo-pharma.comRevenue
$1.6 BillionIndustry
About LEO Pharma
LEO Pharma Org Chart
Is LEO Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if LEO Pharma had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
LEO Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if LEO Pharma is spiking on competitors!
Product Launch: Get notified when LEO Pharma launches new products
Funding: Get notified immidiatlly once LEO Pharma has new funding data
Earning: See what the market has to say on LEO Pharma recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at LEO Pharma
Check if LEO Pharma has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at LEO Pharma
Find 2 more new buyers
Company Profile Activity
Activity Insights
LEO Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
LEO Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about LEO Pharma.
LEO Pharma Tech Stack
A closer look at the technologies used by LEO Pharma
Most Recent Scoops
LEO Pharma News & Media
Er-Kim Signs Exclusive Distribution Agreement with LEO Pharma A/S to Commercialize LOQTORZI® (toripalimab) for Nasopharyngeal and Oesophageal Cancers
Er-Kim and LEO Pharma A/S sign exclusive agreement to launch LOQTORZI® across Central and Eastern Europe, expanding access to innovative cancer treatmentLEO Pharma Announces Positive 16-Week Interim Results for ADHAND Trial for Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis on the Hands who are Candidates for Systemic Therapy
BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma Announces Positive 16-Week Interim Results for ADHAND Trial for TralokinumabLEO Pharma Initiates Phase 2a DELTA NEXT Trial of Delgocitinib Cream in Adults with Mild to Severe Palmoplantar Pustulosis (PPP)
BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma Initiates Phase 2a DELTA NEXT Trial of Delgocitinib Cream in Adults with Mild to Severe Palmoplantar Pustulosis (PPP)Three-month interim report (Q1) 2025 (Unaudited): LEO Pharma Delivers 9% Revenue Growth at Constant Exchange Rates and Doubles Adjusted EBITDA Margin to 16%
BALLERUP, Denmark--(BUSINESS WIRE)--Q1 2025 (Unaudited): LEO Pharma delivers 9% revenue growth at constant exchange rates and doubles adjusted EBITDA margin to 16%
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding LEO Pharma
Founded in 2008, LEO Pharma is a multinational Danish pharmaceutical company specializing in dermatology.... Read More